CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells
- 1 June 2000
- journal article
- research article
- Published by Elsevier BV in Immunity
- Vol. 12 (6), 677-686
- https://doi.org/10.1016/s1074-7613(00)80218-6
Abstract
Immunity against MHC class II− tumors can be mediated by CD4+ T cells in the effector phase through an unknown mechanism. We show that this is IFNγ dependent but does not require IFNγ receptor (IFNγR) expression on tumor cells, T cells, or other hematopoietic cells and that IFNγR expression is not necessary in the priming phase. However, tumor immunity requires IFNγR expression on nonhematopoietic cells in the effector phase and involves inhibition of tumor-induced angiogenesis. This shows that an effective anti-tumor response involves communication between CD4+ T cells and nonhematopoietic cells, most likely within the tumor stroma, and that tumor immunity must not entirely rely on direct tumor cell killing.Keywords
This publication has 42 references indexed in Scilit:
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsThe Journal of Experimental Medicine, 1998
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor SignalingAnnual Review of Immunology, 1997
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- The Molecular Cell Biology of Interferon-gamma and its ReceptorAnnual Review of Immunology, 1993
- Immune Response in Mice that Lack the Interferon-γ ReceptorScience, 1993
- Distribution of interferon‐γ receptor in human tissuesEuropean Journal of Immunology, 1992
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989
- Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell linesEuropean Journal of Cancer and Clinical Oncology, 1986
- Immune interferon: a pleiotropic lymphokine with multiple effectsImmunology Today, 1985